NRNP 6675 Midterm Exam Prep Document | 2026/2027
Edition | 200 Verified Questions
NRNP 6675 Psychiatric Mental Health Nurse Practitioner Care Midterm Exam 2026-2027 QUESTIONS AND
ANSWERS ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive study guide is meticulously designed for the NRNP 6675 Psychiatric Mental
Health Nurse Practitioner (PMHNP) Midterm Exam, reflecting the latest 2026/2027 academic
standards. It contains 200 verified questions with detailed rationales, covering essential topics in
psychiatric assessment, diagnosis, and treatment across the lifespan. Each question is aligned with
current evidence-based practice and national guidelines, ensuring you are fully prepared to excel. The
guide is structured to reinforce critical thinking and clinical reasoning, making it an indispensable
resource for PMHNP students.
Key Features:
Psychiatric assessment and diagnostic criteria (DSM-5-TR)
Pharmacotherapy and psychopharmacology principles
Psychotherapeutic modalities and interventions
Ethical and legal issues in psychiatric care
Cultural and lifespan considerations in mental health
Emergency psychiatry and crisis management
Updates for 2026:
- Updated to reflect 2026/2027 AACN and NONPF competencies
- Revised to include the latest DSM-5-TR diagnostic criteria
- Enhanced rationales with evidence-based practice references
- Added new questions on telehealth and integrated care models
- Aligned with current psychopharmacology guidelines and black box warnings
Abstract:
This academic resource provides a rigorous review for the NRNP 6675 Midterm Examination, focusing on the
advanced practice psychiatric nursing role. The content encompasses comprehensive psychiatric evaluation,
differential diagnosis, and evidence-based treatment planning, with a strong emphasis on psychopharmacology
and psychotherapy. It integrates biopsychosocial, cultural, and ethical considerations, preparing students to
deliver holistic care. The 200 questions are crafted to mirror the exam's format, including multiple-choice and
select-all-that-apply items, each accompanied by a detailed explanation of the correct answer and rationale for
distractors. This guide is an essential tool for mastering the core competencies required for PMHNP certification
and clinical practice.
Keywords:
Psychiatric Mental Health Nurse Practitioner, NRNP 6675, Midterm Exam, DSM-5-TR, Psychopharmacology,
Psychotherapy, Evidence-based practice, 2026/2027
Answer Format:
Each question is followed by the correct answer, a comprehensive rationale explaining the underlying clinical
reasoning, and a brief analysis of why the incorrect options are not appropriate. This format reinforces learning by
clarifying common misconceptions and highlighting key concepts.
Compliance Checklist:
Aligned with the latest PMHNP curriculum standards (2026/2027)
Incorporates DSM-5-TR diagnostic criteria and updates
Page 1
, References evidence-based practice guidelines from APA and ANA
Includes culturally competent and lifespan-focused care considerations
Covers ethical and legal principles in psychiatric nursing
Designed to mirror the actual exam format and difficulty
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of 1-30 Theories, therapeutic relationship, 15%
Psychiatric-Mental Health ethical/legal issues, cultural competence
Nursing
Psychiatric Assessment and 31-70 Mental status exam, diagnostic criteria, 20%
Diagnosis differential diagnosis, screening tools
Psychopharmacology 71-110 Antidepressants, antipsychotics, mood 20%
stabilizers, anxiolytics, stimulants
Psychotherapy and Psychosocial 111-140 CBT, DBT, interpersonal therapy, 15%
Interventions motivational interviewing, group therapy
Specific Psychiatric Disorders 141-180 Mood disorders, anxiety disorders, psychotic 20%
disorders, personality disorders, substance
use
Special Populations and 181-200 Child/adolescent, geriatric, perinatal, crisis 10%
Emergency Psychiatry intervention, suicide risk assessment
Page 2
,Q1. A patient with treatment-resistant depression has failed adequate trials of two
SSRIs and one SNRI. According to current evidence-based guidelines, which
augmentation strategy has the strongest evidence for efficacy in achieving remission?
A. Adding aripiprazole
B. Adding lithium
C. Adding triiodothyronine (T3)
D. Switching to a monoamine oxidase inhibitor (MAOI)
Correct Answer: A. Adding aripiprazole
Rationale: Atypical antipsychotics, particularly aripiprazole, have robust FDA approval
and meta-analytic support as adjunctive therapy in treatment-resistant depression. Lithium
and T3 are also effective but have lower remission rates in comparative trials. MAOIs are
reserved for atypical depression or after multiple failed augmentations due to safety
concerns.
Why Wrong:
B - Lithium augmentation is effective but has a smaller evidence base and more
tolerability issues compared to aripiprazole in current guidelines.
C - T3 augmentation has modest efficacy and is more often used in women or as a
second-line option.
D - MAOIs are not first-line augmentation due to dietary restrictions and drug
interactions, and they are typically used after other options fail.
Reference: American Psychiatric Association. (2023). Practice Guideline for the
Treatment of Patients with Major Depressive Disorder, 3rd ed.
Q2. In a patient with bipolar I disorder who is experiencing a mixed episode, which
medication should be avoided due to the risk of worsening mood instability?
A. Lithium
B. Valproate
C. Lamotrigine
D. Quetiapine
Correct Answer: C. Lamotrigine
Rationale: Lamotrigine has minimal efficacy in acute mania or mixed episodes and is
primarily used for maintenance and bipolar depression. Lithium, valproate, and
quetiapine are all effective in treating mixed episodes, with valproate and atypical
antipsychotics often preferred for rapid stabilization.
Why Wrong:
A - Lithium is effective for mixed episodes, though it may be less rapid than valproate
or antipsychotics.
B - Valproate is a first-line agent for mixed episodes due to its antimanic and
mood-stabilizing properties.
Page 3
, D - Quetiapine is FDA-approved for acute mania and mixed episodes and is
commonly used in clinical practice.
Reference: Goodwin, G. M., et al. (2016). Bipolar disorders, 18(5), 440-450.
Q3. Which of the following best describes the primary mechanism of action of
brexpiprazole in the treatment of schizophrenia?
A. Partial agonism at D2 and 5-HT1A receptors with antagonism at 5-HT2A receptors
B. Full antagonism at D2 and 5-HT2A receptors
C. Selective antagonism at D3 receptors
D. Inhibition of dopamine and norepinephrine reuptake
Correct Answer: A. Partial agonism at D2 and 5-HT1A receptors with antagonism at
5-HT2A receptors
Rationale: Brexpiprazole is a serotonin-dopamine activity modulator: it acts as a partial
agonist at D2 and 5-HT1A receptors and as an antagonist at 5-HT2A receptors. This
unique profile contributes to its efficacy with a lower risk of extrapyramidal symptoms and
metabolic side effects compared to full antagonists.
Why Wrong:
B - Full antagonism at D2 and 5-HT2A is characteristic of first-generation and some
second-generation antipsychotics, not brexpiprazole.
C - Brexpiprazole does not selectively target D3 receptors; its effects are mediated
through D2 partial agonism.
D - Inhibition of dopamine and norepinephrine reuptake is the mechanism of
bupropion, not brexpiprazole.
Reference: Citrome, L. (2015). Brexpiprazole for schizophrenia and as adjunct for major
depressive disorder. International Journal of Clinical Practice, 69(9),
1000-1010.
Q4. A patient with generalized anxiety disorder has not responded to first-line SSRIs
and SNRIs. Which of the following medications has the strongest evidence for use as a
second-line agent in this scenario?
A. Buspirone
B. Pregabalin
C. Hydroxyzine
D. Propranolol
Correct Answer: B. Pregabalin
Rationale: Pregabalin has robust evidence from multiple randomized controlled trials and
meta-analyses for generalized anxiety disorder, and is considered a second-line treatment
in many international guidelines. Buspirone is less effective, especially in patients
previously treated with benzodiazepines. Hydroxyzine and propranolol have limited
Page 4
Edition | 200 Verified Questions
NRNP 6675 Psychiatric Mental Health Nurse Practitioner Care Midterm Exam 2026-2027 QUESTIONS AND
ANSWERS ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive study guide is meticulously designed for the NRNP 6675 Psychiatric Mental
Health Nurse Practitioner (PMHNP) Midterm Exam, reflecting the latest 2026/2027 academic
standards. It contains 200 verified questions with detailed rationales, covering essential topics in
psychiatric assessment, diagnosis, and treatment across the lifespan. Each question is aligned with
current evidence-based practice and national guidelines, ensuring you are fully prepared to excel. The
guide is structured to reinforce critical thinking and clinical reasoning, making it an indispensable
resource for PMHNP students.
Key Features:
Psychiatric assessment and diagnostic criteria (DSM-5-TR)
Pharmacotherapy and psychopharmacology principles
Psychotherapeutic modalities and interventions
Ethical and legal issues in psychiatric care
Cultural and lifespan considerations in mental health
Emergency psychiatry and crisis management
Updates for 2026:
- Updated to reflect 2026/2027 AACN and NONPF competencies
- Revised to include the latest DSM-5-TR diagnostic criteria
- Enhanced rationales with evidence-based practice references
- Added new questions on telehealth and integrated care models
- Aligned with current psychopharmacology guidelines and black box warnings
Abstract:
This academic resource provides a rigorous review for the NRNP 6675 Midterm Examination, focusing on the
advanced practice psychiatric nursing role. The content encompasses comprehensive psychiatric evaluation,
differential diagnosis, and evidence-based treatment planning, with a strong emphasis on psychopharmacology
and psychotherapy. It integrates biopsychosocial, cultural, and ethical considerations, preparing students to
deliver holistic care. The 200 questions are crafted to mirror the exam's format, including multiple-choice and
select-all-that-apply items, each accompanied by a detailed explanation of the correct answer and rationale for
distractors. This guide is an essential tool for mastering the core competencies required for PMHNP certification
and clinical practice.
Keywords:
Psychiatric Mental Health Nurse Practitioner, NRNP 6675, Midterm Exam, DSM-5-TR, Psychopharmacology,
Psychotherapy, Evidence-based practice, 2026/2027
Answer Format:
Each question is followed by the correct answer, a comprehensive rationale explaining the underlying clinical
reasoning, and a brief analysis of why the incorrect options are not appropriate. This format reinforces learning by
clarifying common misconceptions and highlighting key concepts.
Compliance Checklist:
Aligned with the latest PMHNP curriculum standards (2026/2027)
Incorporates DSM-5-TR diagnostic criteria and updates
Page 1
, References evidence-based practice guidelines from APA and ANA
Includes culturally competent and lifespan-focused care considerations
Covers ethical and legal principles in psychiatric nursing
Designed to mirror the actual exam format and difficulty
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of 1-30 Theories, therapeutic relationship, 15%
Psychiatric-Mental Health ethical/legal issues, cultural competence
Nursing
Psychiatric Assessment and 31-70 Mental status exam, diagnostic criteria, 20%
Diagnosis differential diagnosis, screening tools
Psychopharmacology 71-110 Antidepressants, antipsychotics, mood 20%
stabilizers, anxiolytics, stimulants
Psychotherapy and Psychosocial 111-140 CBT, DBT, interpersonal therapy, 15%
Interventions motivational interviewing, group therapy
Specific Psychiatric Disorders 141-180 Mood disorders, anxiety disorders, psychotic 20%
disorders, personality disorders, substance
use
Special Populations and 181-200 Child/adolescent, geriatric, perinatal, crisis 10%
Emergency Psychiatry intervention, suicide risk assessment
Page 2
,Q1. A patient with treatment-resistant depression has failed adequate trials of two
SSRIs and one SNRI. According to current evidence-based guidelines, which
augmentation strategy has the strongest evidence for efficacy in achieving remission?
A. Adding aripiprazole
B. Adding lithium
C. Adding triiodothyronine (T3)
D. Switching to a monoamine oxidase inhibitor (MAOI)
Correct Answer: A. Adding aripiprazole
Rationale: Atypical antipsychotics, particularly aripiprazole, have robust FDA approval
and meta-analytic support as adjunctive therapy in treatment-resistant depression. Lithium
and T3 are also effective but have lower remission rates in comparative trials. MAOIs are
reserved for atypical depression or after multiple failed augmentations due to safety
concerns.
Why Wrong:
B - Lithium augmentation is effective but has a smaller evidence base and more
tolerability issues compared to aripiprazole in current guidelines.
C - T3 augmentation has modest efficacy and is more often used in women or as a
second-line option.
D - MAOIs are not first-line augmentation due to dietary restrictions and drug
interactions, and they are typically used after other options fail.
Reference: American Psychiatric Association. (2023). Practice Guideline for the
Treatment of Patients with Major Depressive Disorder, 3rd ed.
Q2. In a patient with bipolar I disorder who is experiencing a mixed episode, which
medication should be avoided due to the risk of worsening mood instability?
A. Lithium
B. Valproate
C. Lamotrigine
D. Quetiapine
Correct Answer: C. Lamotrigine
Rationale: Lamotrigine has minimal efficacy in acute mania or mixed episodes and is
primarily used for maintenance and bipolar depression. Lithium, valproate, and
quetiapine are all effective in treating mixed episodes, with valproate and atypical
antipsychotics often preferred for rapid stabilization.
Why Wrong:
A - Lithium is effective for mixed episodes, though it may be less rapid than valproate
or antipsychotics.
B - Valproate is a first-line agent for mixed episodes due to its antimanic and
mood-stabilizing properties.
Page 3
, D - Quetiapine is FDA-approved for acute mania and mixed episodes and is
commonly used in clinical practice.
Reference: Goodwin, G. M., et al. (2016). Bipolar disorders, 18(5), 440-450.
Q3. Which of the following best describes the primary mechanism of action of
brexpiprazole in the treatment of schizophrenia?
A. Partial agonism at D2 and 5-HT1A receptors with antagonism at 5-HT2A receptors
B. Full antagonism at D2 and 5-HT2A receptors
C. Selective antagonism at D3 receptors
D. Inhibition of dopamine and norepinephrine reuptake
Correct Answer: A. Partial agonism at D2 and 5-HT1A receptors with antagonism at
5-HT2A receptors
Rationale: Brexpiprazole is a serotonin-dopamine activity modulator: it acts as a partial
agonist at D2 and 5-HT1A receptors and as an antagonist at 5-HT2A receptors. This
unique profile contributes to its efficacy with a lower risk of extrapyramidal symptoms and
metabolic side effects compared to full antagonists.
Why Wrong:
B - Full antagonism at D2 and 5-HT2A is characteristic of first-generation and some
second-generation antipsychotics, not brexpiprazole.
C - Brexpiprazole does not selectively target D3 receptors; its effects are mediated
through D2 partial agonism.
D - Inhibition of dopamine and norepinephrine reuptake is the mechanism of
bupropion, not brexpiprazole.
Reference: Citrome, L. (2015). Brexpiprazole for schizophrenia and as adjunct for major
depressive disorder. International Journal of Clinical Practice, 69(9),
1000-1010.
Q4. A patient with generalized anxiety disorder has not responded to first-line SSRIs
and SNRIs. Which of the following medications has the strongest evidence for use as a
second-line agent in this scenario?
A. Buspirone
B. Pregabalin
C. Hydroxyzine
D. Propranolol
Correct Answer: B. Pregabalin
Rationale: Pregabalin has robust evidence from multiple randomized controlled trials and
meta-analyses for generalized anxiety disorder, and is considered a second-line treatment
in many international guidelines. Buspirone is less effective, especially in patients
previously treated with benzodiazepines. Hydroxyzine and propranolol have limited
Page 4
